SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
QTRN -- a leading service provider to the biotech industry
An SI Board Since November 2002
Posts SubjectMarks Bans Symbol
6 0 0 QTRN
Emcee:  pcyhuang Type:  Unmoderated
We recommend the purchase of Quintiles International (QTRN @$11.84). QTRN is engaged in the provision of full-service contract research, sales and marketing and healthcare policy consulting services to the global pharmaceutical, biotechnology and medical device industries. For the nine months ended 9/02, revenues fell 2% to $1.19 billion. Net income from continuing operations totalled $59.1 million vs. a loss of $248.4 million. We estimate QTRN will earn $.67 per share on $1.6 billion in revenue this year and $.80 per share next year. Projecting an average earnings growth rate of 20%, we estimate QTRN's current PEG ratio to be .9x, substantially below those of its peers'.

moneycentral.msn.com. Click here for detailed company report.

pcyhuang
huangcapital.com
Huang's Mechanical Hedge Investing
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):